top of page
検索

Early Alert: Trividia Health Issues Correction for TRUE METRIX Blood Glucose Monitoring Systems

  • 執筆者の写真: eastanglian
    eastanglian
  • 5 時間前
  • 読了時間: 1分

The U.S. Food and Drug Administration (FDA) is aware that Trividia Health, Inc. has issued an Urgent Medical Device Correction to notify affected customers of corrections to the instructions of for use for all TRUE METRIX, TRUE METRIX AIR, and TRUE METRIX GO Self-Monitoring and TRUE METRIX PRO Professional Monitoring Blood Glucose Systems.


The system displays an E-5 error code for a very high blood glucose event (> 600 mg/dL) or when there is a test strip error. As currently written, the instructions could potentially lead to a delay in treatment if the user does not seek medical attention immediately when they receive an E-5 error code and are experiencing symptoms of high glucose. A delay in treatment may result in serious adverse health consequences, such as dehydration, altered mental status, or death, especially for users with very high blood glucose levels.


As of January 16, Trividia Health has reported 114 serious injuries and one death associated with this issue.


  • - - - - - - - - - - - - - - - - - - - - - -


FDA


Content current as of:

02/17/2026


Regulated Product(s)

Medical Devices



 
 
 

最新記事

すべて表示
2026年5月1日から施行、改正医薬品医療機器等法

厚生労働省は2025年12月26日、2026年5月1日から施行する改正医薬品医療機器等法の趣旨や内容等についての医薬局長通知を発出した。製造管理者の要件等の見直しや、日本薬局方に収載されている医薬品の取扱いの見直し、医薬品等の供給不足時の優先審査等に関する例外などが盛り込まれている。 製造管理者要件の見直しについては、医薬品または体外診断用医薬品の製造販売業者が、薬剤師を置くことが著しく困難である

 
 
 

コメント


© 2023 by CONSULTING SOLUTIONS. Proudly created with Wix.com

  • c-facebook
  • Twitter Classic
  • Google Classic
bottom of page